RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Experimental study of the promotional implications of proprietary prescription drug names
Peinado, S. C., O'Donoghue, A., Betts, K. R., Paquin, R. S., Giombi, K., Arnold, J., Kelly, B. J., & Davis, C. (2024). Experimental study of the promotional implications of proprietary prescription drug names. Therapeutic Innovation and Regulatory Science. https://doi.org/10.1007/s43441-024-00704-8
Background The meaning and characteristics embedded in proprietary drug names have the potential to affect name recall, perceptions of drug benefits and risks, and attitudes toward a drug. In this study, we examined: (1) whether names that reference the drug’s medical indication affect consumers’ and primary care physicians’ (PCPs’) perceptions of the drug and (2) whether names that overstate the drug’s efficacy affect consumers’ and PCPs’ perceptions of the drug.
Methods We conducted an online experiment with 455 PCPs and 450 consumers to test the effects of fictitious proprietary prescription drug names. Participants were randomized to view one neutral drug name, one name that overstated the drug’s efficacy, and five names that referenced the drug’s medical indication.
Results Names that referenced the drug’s medical indication and names that overstated the drug’s benefit both influenced perceptions of efficacy and risk compared to neutral names. For several outcomes, names evoking medical indications had similar effects to those designed to overstate the drug’s efficacy. The patterns of effects were similar for PCPs and consumers.
Conclusion Findings suggest drug names alone can be sufficient to produce attitudes and risk and benefit perceptions about drugs, even in the absence of any information beyond the drug’s medical indication.